Cargando…

Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome

BACKGROUND: Hematologic disorders, including myelodysplastic syndrome (MDS), are difficult to identify in routine hematologic examinations using automated hematology analyzers. However, the practical uses of mean platelet component and mean platelet volume (MPV) measured by these analyzers as screen...

Descripción completa

Detalles Bibliográficos
Autores principales: Masutani, Ryota, Ikemoto, Toshiyuki, Maki, Ayako, Tanada, Hiroko, Iwatani, Yoshinori, Watanabe, Mikio, Takubo, Takayuki, Okada, Yoshikatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266360/
https://www.ncbi.nlm.nih.gov/pubmed/30623074
http://dx.doi.org/10.1002/hsr2.50
_version_ 1783375821746995200
author Masutani, Ryota
Ikemoto, Toshiyuki
Maki, Ayako
Tanada, Hiroko
Iwatani, Yoshinori
Watanabe, Mikio
Takubo, Takayuki
Okada, Yoshikatsu
author_facet Masutani, Ryota
Ikemoto, Toshiyuki
Maki, Ayako
Tanada, Hiroko
Iwatani, Yoshinori
Watanabe, Mikio
Takubo, Takayuki
Okada, Yoshikatsu
author_sort Masutani, Ryota
collection PubMed
description BACKGROUND: Hematologic disorders, including myelodysplastic syndrome (MDS), are difficult to identify in routine hematologic examinations using automated hematology analyzers. However, the practical uses of mean platelet component and mean platelet volume (MPV) measured by these analyzers as screening markers for MDS, remain unclear. METHODS: Mean platelet component and MPV values were measured in the peripheral blood of patients with MDS, aplastic anemia, idiopathic thrombocytopenic purpura, myeloproliferative neoplasms, and in healthy controls using an automated hematologic analyzer. Cutoff values for discriminating between the MDS group and healthy controls were determined by recursive partitioning analysis. RESULTS: Mean platelet component was significantly lower in MDS patients compared with controls, while MPV was significantly higher. Combined cutoff values for MDS diagnosis of <25.3 g/dL for mean platelet component and >10.0 fL for MPV showed a specificity and positive predictive value of 99.9% and 99.1%, respectively. These cutoff values also differentiated between MDS and diagnoses of aplastic anemia, idiopathic thrombocytopenic purpura, and myeloproliferative neoplasms. CONCLUSION: Mean platelet component and MPV may, thus, be useful and convenient screening markers for MDS.
format Online
Article
Text
id pubmed-6266360
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62663602019-01-08 Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome Masutani, Ryota Ikemoto, Toshiyuki Maki, Ayako Tanada, Hiroko Iwatani, Yoshinori Watanabe, Mikio Takubo, Takayuki Okada, Yoshikatsu Health Sci Rep Research Articles BACKGROUND: Hematologic disorders, including myelodysplastic syndrome (MDS), are difficult to identify in routine hematologic examinations using automated hematology analyzers. However, the practical uses of mean platelet component and mean platelet volume (MPV) measured by these analyzers as screening markers for MDS, remain unclear. METHODS: Mean platelet component and MPV values were measured in the peripheral blood of patients with MDS, aplastic anemia, idiopathic thrombocytopenic purpura, myeloproliferative neoplasms, and in healthy controls using an automated hematologic analyzer. Cutoff values for discriminating between the MDS group and healthy controls were determined by recursive partitioning analysis. RESULTS: Mean platelet component was significantly lower in MDS patients compared with controls, while MPV was significantly higher. Combined cutoff values for MDS diagnosis of <25.3 g/dL for mean platelet component and >10.0 fL for MPV showed a specificity and positive predictive value of 99.9% and 99.1%, respectively. These cutoff values also differentiated between MDS and diagnoses of aplastic anemia, idiopathic thrombocytopenic purpura, and myeloproliferative neoplasms. CONCLUSION: Mean platelet component and MPV may, thus, be useful and convenient screening markers for MDS. John Wiley and Sons Inc. 2018-05-02 /pmc/articles/PMC6266360/ /pubmed/30623074 http://dx.doi.org/10.1002/hsr2.50 Text en © 2018 The Authors. Health Science Reports published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Masutani, Ryota
Ikemoto, Toshiyuki
Maki, Ayako
Tanada, Hiroko
Iwatani, Yoshinori
Watanabe, Mikio
Takubo, Takayuki
Okada, Yoshikatsu
Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
title Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
title_full Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
title_fullStr Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
title_full_unstemmed Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
title_short Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
title_sort mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266360/
https://www.ncbi.nlm.nih.gov/pubmed/30623074
http://dx.doi.org/10.1002/hsr2.50
work_keys_str_mv AT masutaniryota meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT ikemototoshiyuki meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT makiayako meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT tanadahiroko meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT iwataniyoshinori meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT watanabemikio meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT takubotakayuki meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome
AT okadayoshikatsu meanplateletcomponentandmeanplateletvolumeasusefulscreeningmarkersformyelodysplasticsyndrome